Goldsby Robert E, Taggart Denah R, Ablin Arthur R
Division of Pediatric Hematology/Oncology, University of California, San Francisco, USA.
Paediatr Drugs. 2006;8(2):71-84. doi: 10.2165/00148581-200608020-00001.
With modern therapies, most children diagnosed with cancer are expected to reach adulthood. Therefore, there are large and ever-increasing numbers of children and young adults in our population who are survivors of childhood cancer. Many of the therapies responsible for improved cancer survival rates can also damage normal cells and tissues. As more children survive cancer, the physical and emotional costs of enduring cancer therapy become increasingly important. Although most childhood cancer survivors are now expected to survive, they remain at risk for relapse, second malignant neoplasms, organ dysfunction, and a negative psychologic impact. Individual risk is quite variable and is dependent on multiple factors including the type and site of cancer, the therapy utilized, and the individual's constitution. The risks are likely to change as we learn more about the specific long-term effects of cancer therapy, develop more refined and targeted therapies, and develop and apply more effective preventative strategies or therapeutic interventions. Guidelines for long-term follow-up have been established and are available to help facilitate appropriate monitoring of and care for potential late effects.
采用现代疗法后,大多数被诊断患有癌症的儿童有望活到成年。因此,我们人口中有大量且数量不断增加的儿童和青年是儿童癌症幸存者。许多提高癌症存活率的疗法也会损害正常细胞和组织。随着越来越多的儿童在癌症中存活下来,承受癌症治疗的身体和情感代价变得越来越重要。虽然现在大多数儿童癌症幸存者有望存活,但他们仍有复发、患第二种恶性肿瘤、器官功能障碍以及产生负面心理影响的风险。个体风险差异很大,取决于多种因素,包括癌症的类型和部位、所采用的治疗方法以及个体体质。随着我们对癌症治疗的具体长期影响了解得更多,开发出更精细、更有针对性的疗法,以及开发和应用更有效的预防策略或治疗干预措施,这些风险可能会发生变化。已经制定了长期随访指南,可用于帮助促进对潜在晚期影响进行适当的监测和护理。